EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-c

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

CAMBRIDGE, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneeri

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-hu

CAMBRIDGE, Mass. , May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneeri

Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo ge

Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve e

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should tak

Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have received an average rating of

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

JPMorgan Chase and Co. cut its holdings in Editas Medicine, Inc. (NASDAQ: EDIT) by 23.0% in the unde

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer